カテゴリー： 世界, 医療/バイオ, Market Monitor Global

世界の先天性高インスリン症（HI）治療薬市場予測2023-2029：ジアゾキシド、オクトレオチド、グルカゴン、その他

【英語タイトル】Congenital hyperinsulinism (HI) Drugs Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが出版した調査資料（MMG23FB2469）・商品コード：MMG23FB2469
・発行会社（調査会社）：Market Monitor Global
・発行日：2023年2月
・ページ数：74
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後2-3営業日）
・調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
・産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

当調査レポートは次の情報を含め、世界の先天性高インスリン症（HI）治療薬市場規模と予測を収録しています。・世界の先天性高インスリン症（HI）治療薬市場：売上、2018年-2023年、2024年-2029年
・世界の先天性高インスリン症（HI）治療薬市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の先天性高インスリン症（HI）治療薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「ジアゾキシド」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

先天性高インスリン症（HI）治療薬のグローバル主要企業は、Novo Nordisk、Eli Lilly、Fresenius Kabi、Taj Pharmaceuticals、Xeris Pharmaceuticals、Novartis、IVAX Pharmaceuticals、Sun Pharmaceutical、Chengdu Tiantaishan Pharmaceutical、Sihuan Pharmaceutical Holdings Groupなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、先天性高インスリン症（HI）治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の先天性高インスリン症（HI）治療薬市場：タイプ別、2018年-2023年、2024年-2029年
世界の先天性高インスリン症（HI）治療薬市場：タイプ別市場シェア、2022年
・ジアゾキシド、オクトレオチド、グルカゴン、その他

世界の先天性高インスリン症（HI）治療薬市場：用途別、2018年-2023年、2024年-2029年
世界の先天性高インスリン症（HI）治療薬市場：用途別市場シェア、2022年
・病院、診療所、その他

世界の先天性高インスリン症（HI）治療薬市場：地域・国別、2018年-2023年、2024年-2029年
世界の先天性高インスリン症（HI）治療薬市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における先天性高インスリン症（HI）治療薬のグローバル売上、2018年-2023年
・主要企業における先天性高インスリン症（HI）治療薬のグローバル売上シェア、2022年
・主要企業における先天性高インスリン症（HI）治療薬のグローバル販売量、2018年-2023年
・主要企業における先天性高インスリン症（HI）治療薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Novo Nordisk、Eli Lilly、Fresenius Kabi、Taj Pharmaceuticals、Xeris Pharmaceuticals、Novartis、IVAX Pharmaceuticals、Sun Pharmaceutical、Chengdu Tiantaishan Pharmaceutical、Sihuan Pharmaceutical Holdings Group

*************************************************************

・調査・分析レポートの概要
先天性高インスリン症（HI）治療薬市場の定義
市場セグメント
世界の先天性高インスリン症（HI）治療薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の先天性高インスリン症（HI）治療薬市場規模
世界の先天性高インスリン症（HI）治療薬市場規模：2022年 VS 2029年
世界の先天性高インスリン症（HI）治療薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの先天性高インスリン症（HI）治療薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の先天性高インスリン症（HI）治療薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：ジアゾキシド、オクトレオチド、グルカゴン、その他
先天性高インスリン症（HI）治療薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院、診療所、その他
先天性高インスリン症（HI）治療薬の用途別グローバル売上・予測

・地域別市場分析
地域別先天性高インスリン症（HI）治療薬市場規模 2022年と2029年
地域別先天性高インスリン症（HI）治療薬売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Novo Nordisk、Eli Lilly、Fresenius Kabi、Taj Pharmaceuticals、Xeris Pharmaceuticals、Novartis、IVAX Pharmaceuticals、Sun Pharmaceutical、Chengdu Tiantaishan Pharmaceutical、Sihuan Pharmaceutical Holdings Group
…

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Congenital hyperinsulinism (HI) Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Congenital hyperinsulinism (HI) Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Congenital hyperinsulinism (HI) Drugs Overall Market Size
2.1 Global Congenital hyperinsulinism (HI) Drugs Market Size: 2022 VS 2029
2.2 Global Congenital hyperinsulinism (HI) Drugs Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Congenital hyperinsulinism (HI) Drugs Sales: 2018-2029
3 Company Landscape
3.1 Top Congenital hyperinsulinism (HI) Drugs Players in Global Market
3.2 Top Global Congenital hyperinsulinism (HI) Drugs Companies Ranked by Revenue
3.3 Global Congenital hyperinsulinism (HI) Drugs Revenue by Companies
3.4 Global Congenital hyperinsulinism (HI) Drugs Sales by Companies
3.5 Global Congenital hyperinsulinism (HI) Drugs Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Congenital hyperinsulinism (HI) Drugs Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Congenital hyperinsulinism (HI) Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Congenital hyperinsulinism (HI) Drugs Players in Global Market
3.8.1 List of Global Tier 1 Congenital hyperinsulinism (HI) Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Congenital hyperinsulinism (HI) Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Congenital hyperinsulinism (HI) Drugs Market Size Markets, 2022 & 2029
4.1.2 Diazoxide
4.1.3 Octreotide
4.1.4 Glucagon
4.1.5 Others
4.2 By Type – Global Congenital hyperinsulinism (HI) Drugs Revenue & Forecasts
4.2.1 By Type – Global Congenital hyperinsulinism (HI) Drugs Revenue, 2018-2023
4.2.2 By Type – Global Congenital hyperinsulinism (HI) Drugs Revenue, 2024-2029
4.2.3 By Type – Global Congenital hyperinsulinism (HI) Drugs Revenue Market Share, 2018-2029
4.3 By Type – Global Congenital hyperinsulinism (HI) Drugs Sales & Forecasts
4.3.1 By Type – Global Congenital hyperinsulinism (HI) Drugs Sales, 2018-2023
4.3.2 By Type – Global Congenital hyperinsulinism (HI) Drugs Sales, 2024-2029
4.3.3 By Type – Global Congenital hyperinsulinism (HI) Drugs Sales Market Share, 2018-2029
4.4 By Type – Global Congenital hyperinsulinism (HI) Drugs Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Congenital hyperinsulinism (HI) Drugs Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Other
5.2 By Application – Global Congenital hyperinsulinism (HI) Drugs Revenue & Forecasts
5.2.1 By Application – Global Congenital hyperinsulinism (HI) Drugs Revenue, 2018-2023
5.2.2 By Application – Global Congenital hyperinsulinism (HI) Drugs Revenue, 2024-2029
5.2.3 By Application – Global Congenital hyperinsulinism (HI) Drugs Revenue Market Share, 2018-2029
5.3 By Application – Global Congenital hyperinsulinism (HI) Drugs Sales & Forecasts
5.3.1 By Application – Global Congenital hyperinsulinism (HI) Drugs Sales, 2018-2023
5.3.2 By Application – Global Congenital hyperinsulinism (HI) Drugs Sales, 2024-2029
5.3.3 By Application – Global Congenital hyperinsulinism (HI) Drugs Sales Market Share, 2018-2029
5.4 By Application – Global Congenital hyperinsulinism (HI) Drugs Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Congenital hyperinsulinism (HI) Drugs Market Size, 2022 & 2029
6.2 By Region – Global Congenital hyperinsulinism (HI) Drugs Revenue & Forecasts
6.2.1 By Region – Global Congenital hyperinsulinism (HI) Drugs Revenue, 2018-2023
6.2.2 By Region – Global Congenital hyperinsulinism (HI) Drugs Revenue, 2024-2029
6.2.3 By Region – Global Congenital hyperinsulinism (HI) Drugs Revenue Market Share, 2018-2029
6.3 By Region – Global Congenital hyperinsulinism (HI) Drugs Sales & Forecasts
6.3.1 By Region – Global Congenital hyperinsulinism (HI) Drugs Sales, 2018-2023
6.3.2 By Region – Global Congenital hyperinsulinism (HI) Drugs Sales, 2024-2029
6.3.3 By Region – Global Congenital hyperinsulinism (HI) Drugs Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Congenital hyperinsulinism (HI) Drugs Revenue, 2018-2029
6.4.2 By Country – North America Congenital hyperinsulinism (HI) Drugs Sales, 2018-2029
6.4.3 US Congenital hyperinsulinism (HI) Drugs Market Size, 2018-2029
6.4.4 Canada Congenital hyperinsulinism (HI) Drugs Market Size, 2018-2029
6.4.5 Mexico Congenital hyperinsulinism (HI) Drugs Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Congenital hyperinsulinism (HI) Drugs Revenue, 2018-2029
6.5.2 By Country – Europe Congenital hyperinsulinism (HI) Drugs Sales, 2018-2029
6.5.3 Germany Congenital hyperinsulinism (HI) Drugs Market Size, 2018-2029
6.5.4 France Congenital hyperinsulinism (HI) Drugs Market Size, 2018-2029
6.5.5 U.K. Congenital hyperinsulinism (HI) Drugs Market Size, 2018-2029
6.5.6 Italy Congenital hyperinsulinism (HI) Drugs Market Size, 2018-2029
6.5.7 Russia Congenital hyperinsulinism (HI) Drugs Market Size, 2018-2029
6.5.8 Nordic Countries Congenital hyperinsulinism (HI) Drugs Market Size, 2018-2029
6.5.9 Benelux Congenital hyperinsulinism (HI) Drugs Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Congenital hyperinsulinism (HI) Drugs Revenue, 2018-2029
6.6.2 By Region – Asia Congenital hyperinsulinism (HI) Drugs Sales, 2018-2029
6.6.3 China Congenital hyperinsulinism (HI) Drugs Market Size, 2018-2029
6.6.4 Japan Congenital hyperinsulinism (HI) Drugs Market Size, 2018-2029
6.6.5 South Korea Congenital hyperinsulinism (HI) Drugs Market Size, 2018-2029
6.6.6 Southeast Asia Congenital hyperinsulinism (HI) Drugs Market Size, 2018-2029
6.6.7 India Congenital hyperinsulinism (HI) Drugs Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Congenital hyperinsulinism (HI) Drugs Revenue, 2018-2029
6.7.2 By Country – South America Congenital hyperinsulinism (HI) Drugs Sales, 2018-2029
6.7.3 Brazil Congenital hyperinsulinism (HI) Drugs Market Size, 2018-2029
6.7.4 Argentina Congenital hyperinsulinism (HI) Drugs Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Congenital hyperinsulinism (HI) Drugs Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Congenital hyperinsulinism (HI) Drugs Sales, 2018-2029
6.8.3 Turkey Congenital hyperinsulinism (HI) Drugs Market Size, 2018-2029
6.8.4 Israel Congenital hyperinsulinism (HI) Drugs Market Size, 2018-2029
6.8.5 Saudi Arabia Congenital hyperinsulinism (HI) Drugs Market Size, 2018-2029
6.8.6 UAE Congenital hyperinsulinism (HI) Drugs Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Novo Nordisk
7.1.1 Novo Nordisk Company Summary
7.1.2 Novo Nordisk Business Overview
7.1.3 Novo Nordisk Congenital hyperinsulinism (HI) Drugs Major Product Offerings
7.1.4 Novo Nordisk Congenital hyperinsulinism (HI) Drugs Sales and Revenue in Global (2018-2023)
7.1.5 Novo Nordisk Key News & Latest Developments
7.2 Eli Lilly
7.2.1 Eli Lilly Company Summary
7.2.2 Eli Lilly Business Overview
7.2.3 Eli Lilly Congenital hyperinsulinism (HI) Drugs Major Product Offerings
7.2.4 Eli Lilly Congenital hyperinsulinism (HI) Drugs Sales and Revenue in Global (2018-2023)
7.2.5 Eli Lilly Key News & Latest Developments
7.3 Fresenius Kabi
7.3.1 Fresenius Kabi Company Summary
7.3.2 Fresenius Kabi Business Overview
7.3.3 Fresenius Kabi Congenital hyperinsulinism (HI) Drugs Major Product Offerings
7.3.4 Fresenius Kabi Congenital hyperinsulinism (HI) Drugs Sales and Revenue in Global (2018-2023)
7.3.5 Fresenius Kabi Key News & Latest Developments
7.4 Taj Pharmaceuticals
7.4.1 Taj Pharmaceuticals Company Summary
7.4.2 Taj Pharmaceuticals Business Overview
7.4.3 Taj Pharmaceuticals Congenital hyperinsulinism (HI) Drugs Major Product Offerings
7.4.4 Taj Pharmaceuticals Congenital hyperinsulinism (HI) Drugs Sales and Revenue in Global (2018-2023)
7.4.5 Taj Pharmaceuticals Key News & Latest Developments
7.5 Xeris Pharmaceuticals
7.5.1 Xeris Pharmaceuticals Company Summary
7.5.2 Xeris Pharmaceuticals Business Overview
7.5.3 Xeris Pharmaceuticals Congenital hyperinsulinism (HI) Drugs Major Product Offerings
7.5.4 Xeris Pharmaceuticals Congenital hyperinsulinism (HI) Drugs Sales and Revenue in Global (2018-2023)
7.5.5 Xeris Pharmaceuticals Key News & Latest Developments
7.6 Novartis
7.6.1 Novartis Company Summary
7.6.2 Novartis Business Overview
7.6.3 Novartis Congenital hyperinsulinism (HI) Drugs Major Product Offerings
7.6.4 Novartis Congenital hyperinsulinism (HI) Drugs Sales and Revenue in Global (2018-2023)
7.6.5 Novartis Key News & Latest Developments
7.7 IVAX Pharmaceuticals
7.7.1 IVAX Pharmaceuticals Company Summary
7.7.2 IVAX Pharmaceuticals Business Overview
7.7.3 IVAX Pharmaceuticals Congenital hyperinsulinism (HI) Drugs Major Product Offerings
7.7.4 IVAX Pharmaceuticals Congenital hyperinsulinism (HI) Drugs Sales and Revenue in Global (2018-2023)
7.7.5 IVAX Pharmaceuticals Key News & Latest Developments
7.8 Sun Pharmaceutical
7.8.1 Sun Pharmaceutical Company Summary
7.8.2 Sun Pharmaceutical Business Overview
7.8.3 Sun Pharmaceutical Congenital hyperinsulinism (HI) Drugs Major Product Offerings
7.8.4 Sun Pharmaceutical Congenital hyperinsulinism (HI) Drugs Sales and Revenue in Global (2018-2023)
7.8.5 Sun Pharmaceutical Key News & Latest Developments
7.9 Chengdu Tiantaishan Pharmaceutical
7.9.1 Chengdu Tiantaishan Pharmaceutical Company Summary
7.9.2 Chengdu Tiantaishan Pharmaceutical Business Overview
7.9.3 Chengdu Tiantaishan Pharmaceutical Congenital hyperinsulinism (HI) Drugs Major Product Offerings
7.9.4 Chengdu Tiantaishan Pharmaceutical Congenital hyperinsulinism (HI) Drugs Sales and Revenue in Global (2018-2023)
7.9.5 Chengdu Tiantaishan Pharmaceutical Key News & Latest Developments
7.10 Sihuan Pharmaceutical Holdings Group
7.10.1 Sihuan Pharmaceutical Holdings Group Company Summary
7.10.2 Sihuan Pharmaceutical Holdings Group Business Overview
7.10.3 Sihuan Pharmaceutical Holdings Group Congenital hyperinsulinism (HI) Drugs Major Product Offerings
7.10.4 Sihuan Pharmaceutical Holdings Group Congenital hyperinsulinism (HI) Drugs Sales and Revenue in Global (2018-2023)
7.10.5 Sihuan Pharmaceutical Holdings Group Key News & Latest Developments
8 Global Congenital hyperinsulinism (HI) Drugs Production Capacity, Analysis
8.1 Global Congenital hyperinsulinism (HI) Drugs Production Capacity, 2018-2029
8.2 Congenital hyperinsulinism (HI) Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Congenital hyperinsulinism (HI) Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Congenital hyperinsulinism (HI) Drugs Supply Chain Analysis
10.1 Congenital hyperinsulinism (HI) Drugs Industry Value Chain
10.2 Congenital hyperinsulinism (HI) Drugs Upstream Market
10.3 Congenital hyperinsulinism (HI) Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Congenital hyperinsulinism (HI) Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of Congenital hyperinsulinism (HI) Drugs in Global Market
Table 2. Top Congenital hyperinsulinism (HI) Drugs Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Congenital hyperinsulinism (HI) Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Congenital hyperinsulinism (HI) Drugs Revenue Share by Companies, 2018-2023
Table 5. Global Congenital hyperinsulinism (HI) Drugs Sales by Companies, (K Units), 2018-2023
Table 6. Global Congenital hyperinsulinism (HI) Drugs Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Congenital hyperinsulinism (HI) Drugs Price (2018-2023) & (US$/Unit)
Table 8. Global Manufacturers Congenital hyperinsulinism (HI) Drugs Product Type
Table 9. List of Global Tier 1 Congenital hyperinsulinism (HI) Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Congenital hyperinsulinism (HI) Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Congenital hyperinsulinism (HI) Drugs Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Congenital hyperinsulinism (HI) Drugs Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Congenital hyperinsulinism (HI) Drugs Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Congenital hyperinsulinism (HI) Drugs Sales (K Units), 2018-2023
Table 15. By Type - Global Congenital hyperinsulinism (HI) Drugs Sales (K Units), 2024-2029
Table 16. By Application – Global Congenital hyperinsulinism (HI) Drugs Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Congenital hyperinsulinism (HI) Drugs Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Congenital hyperinsulinism (HI) Drugs Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Congenital hyperinsulinism (HI) Drugs Sales (K Units), 2018-2023
Table 20. By Application - Global Congenital hyperinsulinism (HI) Drugs Sales (K Units), 2024-2029
Table 21. By Region – Global Congenital hyperinsulinism (HI) Drugs Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Congenital hyperinsulinism (HI) Drugs Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Congenital hyperinsulinism (HI) Drugs Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Congenital hyperinsulinism (HI) Drugs Sales (K Units), 2018-2023
Table 25. By Region - Global Congenital hyperinsulinism (HI) Drugs Sales (K Units), 2024-2029
Table 26. By Country - North America Congenital hyperinsulinism (HI) Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Congenital hyperinsulinism (HI) Drugs Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Congenital hyperinsulinism (HI) Drugs Sales, (K Units), 2018-2023
Table 29. By Country - North America Congenital hyperinsulinism (HI) Drugs Sales, (K Units), 2024-2029
Table 30. By Country - Europe Congenital hyperinsulinism (HI) Drugs Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Congenital hyperinsulinism (HI) Drugs Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Congenital hyperinsulinism (HI) Drugs Sales, (K Units), 2018-2023
Table 33. By Country - Europe Congenital hyperinsulinism (HI) Drugs Sales, (K Units), 2024-2029
Table 34. By Region - Asia Congenital hyperinsulinism (HI) Drugs Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Congenital hyperinsulinism (HI) Drugs Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Congenital hyperinsulinism (HI) Drugs Sales, (K Units), 2018-2023
Table 37. By Region - Asia Congenital hyperinsulinism (HI) Drugs Sales, (K Units), 2024-2029
Table 38. By Country - South America Congenital hyperinsulinism (HI) Drugs Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Congenital hyperinsulinism (HI) Drugs Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Congenital hyperinsulinism (HI) Drugs Sales, (K Units), 2018-2023
Table 41. By Country - South America Congenital hyperinsulinism (HI) Drugs Sales, (K Units), 2024-2029
Table 42. By Country - Middle East & Africa Congenital hyperinsulinism (HI) Drugs Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Congenital hyperinsulinism (HI) Drugs Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Congenital hyperinsulinism (HI) Drugs Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Congenital hyperinsulinism (HI) Drugs Sales, (K Units), 2024-2029
Table 46. Novo Nordisk Company Summary
Table 47. Novo Nordisk Congenital hyperinsulinism (HI) Drugs Product Offerings
Table 48. Novo Nordisk Congenital hyperinsulinism (HI) Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 49. Novo Nordisk Key News & Latest Developments
Table 50. Eli Lilly Company Summary
Table 51. Eli Lilly Congenital hyperinsulinism (HI) Drugs Product Offerings
Table 52. Eli Lilly Congenital hyperinsulinism (HI) Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 53. Eli Lilly Key News & Latest Developments
Table 54. Fresenius Kabi Company Summary
Table 55. Fresenius Kabi Congenital hyperinsulinism (HI) Drugs Product Offerings
Table 56. Fresenius Kabi Congenital hyperinsulinism (HI) Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 57. Fresenius Kabi Key News & Latest Developments
Table 58. Taj Pharmaceuticals Company Summary
Table 59. Taj Pharmaceuticals Congenital hyperinsulinism (HI) Drugs Product Offerings
Table 60. Taj Pharmaceuticals Congenital hyperinsulinism (HI) Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 61. Taj Pharmaceuticals Key News & Latest Developments
Table 62. Xeris Pharmaceuticals Company Summary
Table 63. Xeris Pharmaceuticals Congenital hyperinsulinism (HI) Drugs Product Offerings
Table 64. Xeris Pharmaceuticals Congenital hyperinsulinism (HI) Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 65. Xeris Pharmaceuticals Key News & Latest Developments
Table 66. Novartis Company Summary
Table 67. Novartis Congenital hyperinsulinism (HI) Drugs Product Offerings
Table 68. Novartis Congenital hyperinsulinism (HI) Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 69. Novartis Key News & Latest Developments
Table 70. IVAX Pharmaceuticals Company Summary
Table 71. IVAX Pharmaceuticals Congenital hyperinsulinism (HI) Drugs Product Offerings
Table 72. IVAX Pharmaceuticals Congenital hyperinsulinism (HI) Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 73. IVAX Pharmaceuticals Key News & Latest Developments
Table 74. Sun Pharmaceutical Company Summary
Table 75. Sun Pharmaceutical Congenital hyperinsulinism (HI) Drugs Product Offerings
Table 76. Sun Pharmaceutical Congenital hyperinsulinism (HI) Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 77. Sun Pharmaceutical Key News & Latest Developments
Table 78. Chengdu Tiantaishan Pharmaceutical Company Summary
Table 79. Chengdu Tiantaishan Pharmaceutical Congenital hyperinsulinism (HI) Drugs Product Offerings
Table 80. Chengdu Tiantaishan Pharmaceutical Congenital hyperinsulinism (HI) Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 81. Chengdu Tiantaishan Pharmaceutical Key News & Latest Developments
Table 82. Sihuan Pharmaceutical Holdings Group Company Summary
Table 83. Sihuan Pharmaceutical Holdings Group Congenital hyperinsulinism (HI) Drugs Product Offerings
Table 84. Sihuan Pharmaceutical Holdings Group Congenital hyperinsulinism (HI) Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 85. Sihuan Pharmaceutical Holdings Group Key News & Latest Developments
Table 86. Congenital hyperinsulinism (HI) Drugs Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 87. Global Congenital hyperinsulinism (HI) Drugs Capacity Market Share of Key Manufacturers, 2021-2023
Table 88. Global Congenital hyperinsulinism (HI) Drugs Production by Region, 2018-2023 (K Units)
Table 89. Global Congenital hyperinsulinism (HI) Drugs Production by Region, 2024-2029 (K Units)
Table 90. Congenital hyperinsulinism (HI) Drugs Market Opportunities & Trends in Global Market
Table 91. Congenital hyperinsulinism (HI) Drugs Market Drivers in Global Market
Table 92. Congenital hyperinsulinism (HI) Drugs Market Restraints in Global Market
Table 93. Congenital hyperinsulinism (HI) Drugs Raw Materials
Table 94. Congenital hyperinsulinism (HI) Drugs Raw Materials Suppliers in Global Market
Table 95. Typical Congenital hyperinsulinism (HI) Drugs Downstream
Table 96. Congenital hyperinsulinism (HI) Drugs Downstream Clients in Global Market
Table 97. Congenital hyperinsulinism (HI) Drugs Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Congenital hyperinsulinism (HI) Drugs Segment by Type in 2022
Figure 2. Congenital hyperinsulinism (HI) Drugs Segment by Application in 2022
Figure 3. Global Congenital hyperinsulinism (HI) Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Congenital hyperinsulinism (HI) Drugs Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Congenital hyperinsulinism (HI) Drugs Revenue, 2018-2029 (US$, Mn)
Figure 7. Congenital hyperinsulinism (HI) Drugs Sales in Global Market: 2018-2029 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Congenital hyperinsulinism (HI) Drugs Revenue in 2022
Figure 9. By Type - Global Congenital hyperinsulinism (HI) Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Congenital hyperinsulinism (HI) Drugs Revenue Market Share, 2018-2029
Figure 11. By Type - Global Congenital hyperinsulinism (HI) Drugs Sales Market Share, 2018-2029
Figure 12. By Type - Global Congenital hyperinsulinism (HI) Drugs Price (US$/Unit), 2018-2029
Figure 13. By Application - Global Congenital hyperinsulinism (HI) Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Congenital hyperinsulinism (HI) Drugs Revenue Market Share, 2018-2029
Figure 15. By Application - Global Congenital hyperinsulinism (HI) Drugs Sales Market Share, 2018-2029
Figure 16. By Application - Global Congenital hyperinsulinism (HI) Drugs Price (US$/Unit), 2018-2029
Figure 17. By Region - Global Congenital hyperinsulinism (HI) Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Congenital hyperinsulinism (HI) Drugs Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Congenital hyperinsulinism (HI) Drugs Revenue Market Share, 2018-2029
Figure 20. By Region - Global Congenital hyperinsulinism (HI) Drugs Sales Market Share, 2018-2029
Figure 21. By Country - North America Congenital hyperinsulinism (HI) Drugs Revenue Market Share, 2018-2029
Figure 22. By Country - North America Congenital hyperinsulinism (HI) Drugs Sales Market Share, 2018-2029
Figure 23. US Congenital hyperinsulinism (HI) Drugs Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Congenital hyperinsulinism (HI) Drugs Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Congenital hyperinsulinism (HI) Drugs Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Congenital hyperinsulinism (HI) Drugs Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Congenital hyperinsulinism (HI) Drugs Sales Market Share, 2018-2029
Figure 28. Germany Congenital hyperinsulinism (HI) Drugs Revenue, (US$, Mn), 2018-2029
Figure 29. France Congenital hyperinsulinism (HI) Drugs Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Congenital hyperinsulinism (HI) Drugs Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Congenital hyperinsulinism (HI) Drugs Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Congenital hyperinsulinism (HI) Drugs Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Congenital hyperinsulinism (HI) Drugs Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Congenital hyperinsulinism (HI) Drugs Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Congenital hyperinsulinism (HI) Drugs Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Congenital hyperinsulinism (HI) Drugs Sales Market Share, 2018-2029
Figure 37. China Congenital hyperinsulinism (HI) Drugs Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Congenital hyperinsulinism (HI) Drugs Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Congenital hyperinsulinism (HI) Drugs Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Congenital hyperinsulinism (HI) Drugs Revenue, (US$, Mn), 2018-2029
Figure 41. India Congenital hyperinsulinism (HI) Drugs Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Congenital hyperinsulinism (HI) Drugs Revenue Market Share, 2018-2029
Figure 43. By Country - South America Congenital hyperinsulinism (HI) Drugs Sales Market Share, 2018-2029
Figure 44. Brazil Congenital hyperinsulinism (HI) Drugs Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Congenital hyperinsulinism (HI) Drugs Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Congenital hyperinsulinism (HI) Drugs Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Congenital hyperinsulinism (HI) Drugs Sales Market Share, 2018-2029
Figure 48. Turkey Congenital hyperinsulinism (HI) Drugs Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Congenital hyperinsulinism (HI) Drugs Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Congenital hyperinsulinism (HI) Drugs Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Congenital hyperinsulinism (HI) Drugs Revenue, (US$, Mn), 2018-2029
Figure 52. Global Congenital hyperinsulinism (HI) Drugs Production Capacity (K Units), 2018-2029
Figure 53. The Percentage of Production Congenital hyperinsulinism (HI) Drugs by Region, 2022 VS 2029
Figure 54. Congenital hyperinsulinism (HI) Drugs Industry Value Chain
Figure 55. Marketing Channels


★調査レポート[世界の先天性高インスリン症（HI）治療薬市場予測2023-2029：ジアゾキシド、オクトレオチド、グルカゴン、その他] (コード：MMG23FB2469)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の先天性高インスリン症（HI）治療薬市場予測2023-2029：ジアゾキシド、オクトレオチド、グルカゴン、その他]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の尿路感染症（UTI）治療薬市場予測2023-2029：ジェネリック医薬品、先発医薬品
  • 世界の咳喘息（CVA）治療薬市場予測2023-2029：気管支拡張剤、ロイコトリエン拮抗剤、肥満細胞安定剤、コルチコステロイド、モノクローナル抗体
  • 世界の多発性硬化症（MS）治療薬市場予測2023-2029：コパキソン（グラチラマー酢酸塩）、ノバントロン（ミトキサントロン）、ジレニア（フィンゴリモド、Fty720）、オーバジオ（テリフルノミド）、テクフィデラ（フマル酸ジメチル）、フィラテグラスト（Sb683699、T-0047）、シポニモド（Baf312）、その他
  • 世界の経口ペプチド薬市場予測2023-2029：リナクロチド、インスリン、プレカナチド、シクロスポリン、オクトレオチド
  • 世界の経口ペプチド療法市場予測2023-2029：リナクロチド、インスリン、プレカナチド、シクロスポリン、オクトレオチド
  • 世界の先端巨大症治療市場予測2023-2029：オクトレオチド、パシレオチド、ランレオチド、ペグビソマント
  • 経口タンパク質・ペプチドのグローバル市場：リナクロチド、プレカナチド、カルシトニン、インスリン、オクトレオチド
  • 世界の小児用ADHD治療薬市場予測2023-2029：錠剤、経口液、その他
  • 世界の抗統合失調症薬市場予測2023-2029：錠剤、カプセル、その他

    • ◆H&Iグローバルリサーチのお客様（例）◆